Alnylam Pharmaceuticals, Inc. (ALNY)
415.21
-14.81
(-3.44%)
USD |
NASDAQ |
Dec 09, 16:00
415.60
+0.39
(+0.09%)
After-Hours: 20:00
Alnylam Pharmaceuticals EPS Diluted (Quarterly): 1.840 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Pfizer Inc. | 0.6197 |
| Glaukos Corp. | -0.2828 |
| Bristol Myers Squibb Co. | 1.079 |
| BridgeBio Pharma, Inc. | -0.9525 |
| Vertex Pharmaceuticals, Inc. | 4.204 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 251.08M |
| Revenue (Quarterly) | 1.249B |
| Total Expenses (Quarterly) | 997.94M |
| Enterprise Value | 54.90B |
| Gross Profit Margin (Quarterly) | 83.98% |
| Profit Margin (Quarterly) | 20.10% |
| Earnings Yield | 0.06% |
| Operating Earnings Yield | 0.48% |
| Normalized Earnings Yield | 0.3733 |